miércoles, 17 de mayo de 2017

Journal for ImmunoTherapy of Cancer | Immunotherapy Biomarkers

Journal for ImmunoTherapy of Cancer | Immunotherapy Biomarkers

Biomed Central

Journal for ImmunoTherapy of Cancer

JITC logo

Journal for ImmunoTherapy of Cancer is the official journal of the Society for Immunotherapy of Cancer (SITC)

Immunotherapy Biomarkers

Section edited by Lisa H. Butterfield, PhD
Predictive/prognostic biomarker studies, gene expression studies in cancer immunotherapy, serological immune biomarkers, multiparameter flow cytometry-defined immune biomarkers, high content immunohistological studies, clinical trial analyses and identification of novel immune biomarkers.


    Differential phenotypes of memory CD4 and CD8 T cells in the spleen and peripheral tissues following immunostimulatory therapy

    Studies assessing immune parameters typically utilize human PBMCs or murine splenocytes to generate data that is interpreted as representative of immune status. Using splenocytes, we have shown memory CD4-T ce...
    Gail D. Sckisel, Annie Mirsoian, Christine M. Minnar, Marka Crittenden, Brendan Curti, Jane Q. Chen, Bruce R. Blazar, Alexander D. Borowsky, Arta M. Monjazeb and William J. Murphy
    Journal for ImmunoTherapy of Cancer 2017 5:33
    Published on: 18 April 2017

    Nuclear IRF-1 expression as a mechanism to assess “Capability” to express PD-L1 and response to PD-1 therapy in metastatic melanoma

    Predictive biomarkers for antibodies against programmed death 1 (PD-1) remain a major unmet need in metastatic melanoma. Specifically, response is seen in tumors that do not express programmed death ligand 1 (...
    James W. Smithy, Lauren M. Moore, Vasiliki Pelekanou, Jamaal Rehman, Patricia Gaule, Pok Fai Wong, Veronique M. Neumeister, Mario Sznol, Harriet M. Kluger and David L. Rimm
    Journal for ImmunoTherapy of Cancer 2017 5:25
    Published on: 21 March 2017

    Immunotherapy biomarkers 2016: overcoming the barriers

    This report summarizes the symposium, ‘Immunotherapy Biomarkers 2016: Overcoming the Barriers’, which was held on April 1, 2016 at the National Institutes of Health in Bethesda, Maryland. The symposium, cospon...
    James L. Gulley, Jay A. Berzofsky, Marcus O. Butler, Alessandra Cesano, Bernard A. Fox, Sacha Gnjatic, Sylvia Janetzki, Shyam Kalavar, Vaios Karanikas, Samir N. Khleif, Ilan Kirsch, Peter P. Lee, Cristina Maccalli, Holden Maecker, Jeffrey Schlom, Barbara Seliger…
    Journal for ImmunoTherapy of Cancer 2017 5:29
    Published on: 21 March 2017

    Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody

    Multiple anti-PD-L1/PD-1 checkpoint monoclonal antibodies (MAb) have shown clear evidence of clinical benefit. All except one have been designed or engineered to omit the possibility to mediate antibody-depend...
    Renee N. Donahue, Lauren M. Lepone, Italia Grenga, Caroline Jochems, Massimo Fantini, Ravi A. Madan, Christopher R. Heery, James L. Gulley and Jeffrey Schlom
    Journal for ImmunoTherapy of Cancer 2017 5:20
    Published on: 21 February 2017

    Gene expression markers of Tumor Infiltrating Leukocytes

    Assays of the abundance of immune cell populations in the tumor microenvironment promise to inform immune oncology research and the choice of immunotherapy for individual patients. We propose to measure the in...
    Patrick Danaher, Sarah Warren, Lucas Dennis, Leonard D’Amico, Andrew White, Mary L. Disis, Melissa A. Geller, Kunle Odunsi, Joseph Beechem and Steven P. Fling
    Journal for ImmunoTherapy of Cancer 2017 5:18
    Published on: 21 February 2017

    Validation of biomarkers to predict response to immunotherapy in cancer: Volume II — clinical validation and regulatory considerations

    There is growing recognition that immunotherapy is likely to significantly improve health outcomes for cancer patients in the coming years. Currently, while a subset of patients experience substantial clinical...
    Kevin K. Dobbin, Alessandra Cesano, John Alvarez, Rachael Hawtin, Sylvia Janetzki, Ilan Kirsch, Giuseppe V. Masucci, Paul B. Robbins, Senthamil R. Selvan, Howard Z. Streicher, Jenny Zhang, Lisa H. Butterfield and Magdalena Thurin
    Journal for ImmunoTherapy of Cancer 2016 4:77
    Published on: 15 November 2016

    Validation of biomarkers to predict response to immunotherapy in cancer: Volume I — pre-analytical and analytical validation

    Immunotherapies have emerged as one of the most promising approaches to treat patients with cancer. Recently, there have been many clinical successes using checkpoint receptor blockade, including T cell inhibi...
    Giuseppe V. Masucci, Alessandra Cesano, Rachael Hawtin, Sylvia Janetzki, Jenny Zhang, Ilan Kirsch, Kevin K. Dobbin, John Alvarez, Paul B. Robbins, Senthamil R. Selvan, Howard Z. Streicher, Lisa H. Butterfield and Magdalena Thurin
    Journal for ImmunoTherapy of Cancer 2016 4:76
    Published on: 15 November 2016

    Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide

    Cancer vaccines aim at eliciting not only an immune response against specific tumor antigens, but also at enhancing a preexisting immunity against the tumor. In this context, we recently reported on the levels...
    Ioannis F. Voutsas, Eleftheria A. Anastasopoulou, Panagiotis Tzonis, Michael Papamichail, Sonia A. Perez and Constantin N. Baxevanis
    Journal for ImmunoTherapy of Cancer 2016 4:75
    Published on: 15 November 2016

    Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial

    Depletion of CD25+ Tregs improves anti-tumor immunity in preclinical models. Denileukin diftitox is a recombinant fusion protein of human IL-2 and diptheria toxin fragment that also can kill CD25+ T cells. Prior ...
    Jason J. Luke, Yuanyuan Zha, Karen Matijevich and Thomas F. Gajewski
    Journal for ImmunoTherapy of Cancer 2016 4:35
    Published on: 21 June 2016

    Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients

    Preclinical studies suggest a synergistic effect between radiation, immunotherapy and anti-angiogenic therapy, although the mechanisms are unclear. Angiogenic cytokines are known to affect the immune system, a...
    Vishwajith Sridharan, Danielle N. Margalit, Stephanie A. Lynch, Mariano Severgnini, F. Stephen Hodi, Robert I. Haddad, Roy B. Tishler and Jonathan D. Schoenfeld
    Journal for ImmunoTherapy of Cancer 2016 4:32
    Published on: 21 June 2016

    Immune monitoring technology primer: clinical validation for predictive markers

    Recent biotechnological developments have resulted in increasing interest in immunology biomarkers. These biomarkers have potential clinical utility in the near future as predictors of treatment response. Henc...
    Kevin K. Dobbin
    Journal for ImmunoTherapy of Cancer 2015 3:40
    Published on: 20 October 2015
    The Erratum to this article has been published in Journal for ImmunoTherapy of Cancer 2015 3:56

    Prognostic impact of circulating Her-2-reactive T-cells producing pro- and/or anti-inflammatory cytokines in elderly breast cancer patients

    Treating elderly breast cancer patients remains a challenge but the increasing availability of immunotherapeutic approaches instills optimism that these tumours may also be susceptible to immune control. Becau...
    Jithendra Kini Bailur, Evelyna Derhovanessian, Brigitte Gueckel and Graham Pawelec
    Journal for ImmunoTherapy of Cancer 2015 3:45
    Published on: 20 October 2015

    Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma

    Adoptive T cell therapy (ACT) has shown great promise in melanoma, with over 50 % response rate in patients where autologous tumor-reactive tumor-infiltrating lymphocytes (TIL) can be cultured and expanded. A ...
    Zipei Feng, Sachin Puri, Tarsem Moudgil, William Wood, Clifford C. Hoyt, Chichung Wang, Walter J. Urba, Brendan D. Curti, Carlo B. Bifulco and Bernard A. Fox
    Journal for ImmunoTherapy of Cancer 2015 3:47
    Published on: 20 October 2015

No hay comentarios:

Publicar un comentario